Kim Barbara Luley

Biomarker-defined Benefit from FLOT Plus Nivolumab in Metastatic Gastroesophageal Cancer: Extended Follow-Up and Immune-Inflammatory markers of the Phase II IKF-AIO-Moonlight Trial

Michael Masetti, Alexander Edward Nieto, Sylvie Lorenzen, Thorsten Oliver Goetze et autres

Background First-line treatment of PD-L1–positive advanced gastroesophageal adenocarcinoma (GEA) combines doublet 5-FU/platinum with anti–PD1 inhibition. While triplet chemotherapy (FLOT/TFOX) has demonstrated efficacy alone, data on the combination of FLOT with immunotherapy remain sparse. Given the intensity of triplet immunochemotherapy in a palliative …

de (code pays fourni par la source)

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C. Thuss-Patience, Jorge Riera‐Knorrenschild et autres

In the version of this article initially published, funding information did not acknowledge the sponsor of the trial is the Frankfurt Institute of Clinical Cancer Research IKF GmbH and that financial support and drug supply for the conduct of the trial was …

de (code pays fourni par la source)

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C. Thuss-Patience, Jorge Riera‐Knorrenschild et autres

This multi-cohort study evaluates whether dual immune checkpoint inhibition with nivolumab and ipilimumab in parallel or sequentially, or triplet chemotherapy with nivolumab can enhance efficacy as first-line therapy for advanced or metastatic gastroesophageal adenocarcinoma. Patients are randomized 1:1 to Arm A (mFOLFOX …

de (code pays fourni par la source)

Biomarker-defined Benefit from FLOT Plus Nivolumab in Metastatic Gastroesophageal Cancer: Extended Follow-Up and Immune-Inflammatory markers of the Phase II IKF-AIO-Moonlight Trial

Michael Masetti, Alexander Edward Nieto, Sylvie Lorenzen, Thorsten Oliver Goetze et autres

de (code pays fourni par la source)

Personalized Combined Nutrition & Exercise Intervention in Newly Diagnosed Cancer Patients - a Trial Protocol

Sebastian Theurich, Timo Niels, Hansjörg Baurecht, Christine Welker et autres

The prevalences of malnutrition and sarcopenia are high already at the time of cancer diagnosis and significantly impact on treatment outcomes. Here, we present the protocol of a multicenter, randomized controlled trial to evaluate the efficacy of personalized, combined nutrition and physical …

de, us, kr (code pays fourni par la source)

456P Mutational signature dynamics in gastric and esophageal cancers: A retrospective comprehensive genomic analysis

Niaz Bahadur Khan, Axel Künstner, Kim Barbara Luley, Stephanie M. J. Fliedner et autres

de (code pays fourni par la source)

407P Immune composition-based efficacy assessment of first-line immune-chemotherapy combinations in gastroesophageal cancer: Subgroup analysis of the phase II IKF-AIO-STO-0417 / moonlight trial

Michael Masetti, Maria Angela Nieto, S. Lorenzen, S-E. Al-Batran et autres

de (code pays fourni par la source)

Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors–A randomized clinical trial (IKF-010)

Thorsten Oliver Goetze, Ralf‐Dieter Hofheinz, Ingeborg Roetzer, Wolfgang Blau et autres

PURPOSE: Many cancer patients rely on home parenteral nutrition (HPN), requiring intensive nursing care and facing higher infection risks. Multi-chamber bags (MCB) for individualized HPN could reduce manipulation, enhance patient autonomy, and lower infection risks. This study (IKF-t01/PEKANNUSS) compares MCB-based HPN to …

de, us (code pays fourni par la source)

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.

Thorsten Oliver Goetze, Arndt Vogel, Johann Pratschke, Matthias Behrend et autres

4008 Background: Radical surgical resection represents the only potentially curative treatment option for Biliary Tract Cancer (BTC) and (incidental) Gallbladder Carcinoma ((I)GBC). Nevertheless, 5-year OS is only 20–40% after curatively intended resection and data regarding pure adjuvant chemotherapy in BTCs are currently …

de, ca (code pays fourni par la source)

Welche Immuntherapien sind heute schon Standard? Und mit welchen Nebenwirkungen muss man bei Immuntherapien rechnen?

Zhala Gasimova, Cyrus Khandanpour, Kim Barbara Luley, Nikolas Christian Cornelius von Bubnoff

In comparison to earlier treatment standards (including chemotherapy, radiation therapy, and surgery), immunotherapy has significantly improved patients' survival and quality of life. Immunotherapy is ultimately a broad term that encompasses a variety of therapeutics. Immunotherapeutic approaches have firmly established themselves as a …

de (code pays fourni par la source)

LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, Jorge Riera Knorrenschild et autres

de (code pays fourni par la source)

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

Michael Masetti, Salah‐Eddin Al‐Batran, Thorsten Oliver Goetze, Peter C Thuss-Patience et autres

FOLFOX plus nivolumab represents a standard of care for first-line therapy of advanced gastroesophageal cancer (aGEC) with positive PD-L1 expression. The efficacy of second-line VEGFR-2 inhibition with ramucirumab (RAM) plus chemotherapy after progression to immunochemotherapy remains unclear. Medical records of patients with …

de (code pays fourni par la source)